Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

11/12/24 9:55:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EWTX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 EDGEWISE THERAPEUTICS INC COMMON STOCK Cusip #28036F105 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #28036F105 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 651,541 Item 6: 0 Item 7: 653,207 Item 8: 0 Item 9: 653,207 Item 11: 0.696% Item 12: HC Cusip #28036F105 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 653,207 Item 8: 0 Item 9: 653,207 Item 11: 0.696% Item 12: IN Item 1(a). Name of Issuer: EDGEWISE THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 1715 38TH ST BOULDER, CO 80301 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 28036F105 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 653,207 (b) Percent of Class: 0.696% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 653,207 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of EDGEWISE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of EDGEWISE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of EDGEWISE THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $EWTX alert in real time by email

Recent Analyst Ratings for

$EWTX

Date	Price Target	Rating	Analyst
7/9/2026	$51.00	Outperform	Oppenheimer
9/25/2025	$20.00	Neutral	Goldman
7/30/2025	$46.00	Strong Buy	Raymond James
6/30/2025	$42.00	Buy	H.C. Wainwright
4/30/2025	$41.00	Buy	Guggenheim
4/2/2025	$14.00	Sector Outperform → Sector Perform	Scotiabank
3/7/2025	$50.00	Sector Outperform	Scotiabank
1/22/2025	$30.00	Hold	Stifel

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

11/12/24 9:55:14 AM ET

$EWTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EWTX alert in real time by email

Recent Analyst Ratings for

$EWTX

Date	Price Target	Rating	Analyst
7/9/2026	$51.00	Outperform	Oppenheimer
9/25/2025	$20.00	Neutral	Goldman
7/30/2025	$46.00	Strong Buy	Raymond James
6/30/2025	$42.00	Buy	H.C. Wainwright
4/30/2025	$41.00	Buy	Guggenheim
4/2/2025	$14.00	Sector Outperform → Sector Perform	Scotiabank
3/7/2025	$50.00	Sector Outperform	Scotiabank
1/22/2025	$30.00	Hold	Stifel

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$EWTX

Amendment: SEC Form SC 13G/A filed by Edgewise Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$EWTX

$EWTX
Analyst Ratings

Oppenheimer initiated coverage on Edgewise Therapeutics with a new price target

Goldman initiated coverage on Edgewise Therapeutics with a new price target

Raymond James initiated coverage on Edgewise Therapeutics with a new price target

$EWTX
SEC Filings

Amendment: Edgewise Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

Edgewise Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Edgewise Therapeutics Inc.

$EWTX
Insider Trading

SEC Form 4 filed by Director Root Jonathan D

Chief Scientific Officer Russell Alan J exercised 200,000 shares at a strike of $0.36 and sold $7,881,402 worth of shares (200,000 units at $39.41) (SEC Form 4)

Director Fox Jonathan C was granted 319 shares, increasing direct ownership by 1% to 24,833 units (SEC Form 4)

$EWTX
Press Releases

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

$EWTX
Insider Purchases

Director Fox Jonathan C bought $199,403 worth of shares (10,700 units at $18.64), increasing direct ownership by 82% to 23,702 units (SEC Form 4)

Director Thompson Peter A. bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

Director Orbimed Advisors Llc bought $10,000,000 worth of shares (496,771 units at $20.13) (SEC Form 4)

$EWTX
Leadership Updates

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

$EWTX
Financials

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

$EWTX
Large Ownership Changes